Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01839448
Other study ID # AOI/2012/VC-01
Secondary ID 2013-A00277-38
Status Completed
Phase N/A
First received April 22, 2013
Last updated January 2, 2018
Start date March 27, 2014
Est. completion date August 16, 2017

Study information

Verified date January 2018
Source Centre Hospitalier Universitaire de Nimes
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The main objective of the study is to estimate and compare the percentage of patients with abnormal glucose metabolism at 4-12 weeks postpartum between two groups: patients diagnosed with gestational diabetes before or after 24 weeks of pregnancy. Abnormal glucose metabolism is defined as type 2 diabetes, glucose intolerance or impaired fasting glucose.


Description:

The secondary objectives of this study are to compare between the two groups:

A. the rate of type 2 diabetes only, glucose intolerance only, impaired fasting glucose only, and patients requiring insulin at 4-12 weeks postpartum

B. rates of maternal and obstetric complications

C. risk factors (age, body mass index, personal history of gestational diabetes or macrosomia, first degree family history of diabetes).

D. For fasting glucose done before 24SA, we will calculate the optimal threshold for predicting abnormal glucose metabolism in the immediate postpartum period among women with gestational diabetes.


Recruitment information / eligibility

Status Completed
Enrollment 500
Est. completion date August 16, 2017
Est. primary completion date August 16, 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- The patient must have given her informed and signed consent

- The patient must be insured or beneficiary of a health insurance plan

- The patient is available for 10 months of follow-up

- The patient is pregnant and consulting before 24 weeks of amenorrhea AND has at least one of the following risk factors: age > 35 years; body mass index > 25; family history of type 2 diabetes; history of gestational diabetes; history of macrosomia.

- The patient has a fasting blood glucose level >= 0.92 g/l before 24 weeks of amenorrhea OR a fasting blood glucose level < 0.92 g/l before 24 weeks of amenorrhea AND an abnormal oral glucose tolerance test (75 g of glucose) between 24 and 28 weeks of amenorrhea (normal values are set at T0 < 0.92 g/l; T60 < 1.80 g/l; T120 < 1.53 g/l).

Exclusion Criteria:

- The patient is participating in another study

- The patient is in an exclusion period determined by a previous study, with the exception of the following studies: Papillo PMA (RCB 2013-A00538-37), LXRs (RCB 2009-A00968-49), GrossPath (RCB 2014-A01120-47), BAKRI (RCB 2013-A00914-41), OASIS II (RCB 2013-A00773-42), ElastoMAP (RCB 2013-A01148-37), ElastoDéclench (RCB 2014-A00828-39) and UpSideDown (RCB 2014-A01921-46).

- The patient is under judicial protection, under tutorship or curatorship

- The patient refuses to sign the consent

- It is impossible to correctly inform the patient

- The patient cannot read French

- The patient has a known history of type 2 diabetes

- The patient is diagnosed with type 2 diabetes during pregnancy (fasting blood glucose level > 1.26 g/l)

- The patient has a contra-indication for a treatment necessary for this study

- The patient is taking chronic or intermittent oral or inhaled corticosteroids, or a ß2 agonist treatment for a previous disease or a disease discovered during pregnancy within one week preceding the fasting glucose or oral glucose tolerance test.

Study Design


Intervention

Biological:
Post-partum oral glucose tolerance test
All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.

Locations

Country Name City State
France CH d'Arles - Hôpital Joseph Imbert Arles Cedex
France CHU de Montpellier - Hôpital Lapeyronie Montpellier
France CHU de Montpellier - Hôpital Arnaud de Villeneuve Montpellier Cedex 5
France CHU de Nîmes - Hôpital Universitaire Carémeau Nîmes Cedex 9

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other Age baseline (day 0)
Other Body mass index baseline (day 0)
Other Number of pregnancies baseline (day 0)
Primary Presence/absence of abnormal glucose metabolism Includes type 2 diabetes, glucose intolerance and impaired fasting glucose 4 to12 weeks post-partum
Secondary Presence/absence of type 2 diabetes 4 to 12 weeks post partum
Secondary Presence/absence of glucose intolerance 4 to 12 weeks post-partum
Secondary Presence/absence of impaired fasting glucose American definition: defined as between 1 and 1.26 g/l 4 to12 weeks post-partum
Secondary Presence/absence of impaired fasting glucose European definition: defined as between 1.1 and 1.26 g/l 4 to12 weeks post-partum
Secondary Patient requiring insulin: yes/no 4 to12 weeks post-partum
Secondary Presence/absence of complications This includes a yes/no response for each of the following: caesarean section, hypertension, preeclampsia, urinary tract infection, macrosomia, dystocia, neonatal transfer, respiratory distress, threat of premature birth. 4 to12 weeks post-partum
Secondary Baby's weight at birth (kg) 4 to 12 weeks post-partum
Secondary Weeks of amenorrhea (duration of pregnancy in weeks/ gestational age) 4 to 12 weeks post-partum
Secondary Patient was older than 35 years of age at beginning of pregnancy? yes/no baseline (day 0)
Secondary Body mass index > 25 at beginning of pregnancy? yes/no baseline (day 0)
Secondary First degree family history of type 2 diabetes? yes/no baseline (day 0)
Secondary History of gestational diabetes? yes/no baseline (day 0)
Secondary History of macrosomia? yes/no baseline (day 0)
Secondary Fasting glucose (g/l) before 24 weeks of amenorrhea
Secondary Oral glucose tolerance test results if necessary 24 to 28 weeks of amenorrhea
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A